Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Idiopathic inflammatory myopathies

IE. Lundberg, M. Fujimoto, J. Vencovsky, R. Aggarwal, M. Holmqvist, L. Christopher-Stine, AL. Mammen, FW. Miller

. 2021 ; 7 (1) : 86. [pub] 20211202

Language English Country Great Britain

Document type Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't, Review

E-resources Online Full text

NLK ProQuest Central from 2015-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2015-01-01 to 1 year ago

Idiopathic inflammatory myopathies (IIM), also known as myositis, are a heterogeneous group of autoimmune disorders with varying clinical manifestations, treatment responses and prognoses. Muscle weakness is usually the classical clinical manifestation but other organs can be affected, including the skin, joints, lungs, heart and gastrointestinal tract, and they can even result in the predominant manifestations, supporting that IIM are systemic inflammatory disorders. Different myositis-specific auto-antibodies have been identified and, on the basis of clinical, histopathological and serological features, IIM can be classified into several subgroups - dermatomyositis (including amyopathic dermatomyositis), antisynthetase syndrome, immune-mediated necrotizing myopathy, inclusion body myositis, polymyositis and overlap myositis. The prognoses, treatment responses and organ manifestations vary among these groups, implicating different pathophysiological mechanisms in each subtype. A deeper understanding of the molecular pathways underlying the pathogenesis and identifying the auto-antigens of the immune reactions in these subgroups is crucial to improving outcomes. New, more homogeneous subgroups defined by auto-antibodies may help define disease mechanisms and will also be important in future clinical trials for the development of targeted therapies and in identifying biomarkers to guide treatment decisions for the individual patient.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011754
003      
CZ-PrNML
005      
20220506131506.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41572-021-00321-x $2 doi
035    __
$a (PubMed)34857798
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Lundberg, Ingrid E $u Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden. ingrid.lundberg@ki.se $1 https://orcid.org/0000000260689212
245    10
$a Idiopathic inflammatory myopathies / $c IE. Lundberg, M. Fujimoto, J. Vencovsky, R. Aggarwal, M. Holmqvist, L. Christopher-Stine, AL. Mammen, FW. Miller
520    9_
$a Idiopathic inflammatory myopathies (IIM), also known as myositis, are a heterogeneous group of autoimmune disorders with varying clinical manifestations, treatment responses and prognoses. Muscle weakness is usually the classical clinical manifestation but other organs can be affected, including the skin, joints, lungs, heart and gastrointestinal tract, and they can even result in the predominant manifestations, supporting that IIM are systemic inflammatory disorders. Different myositis-specific auto-antibodies have been identified and, on the basis of clinical, histopathological and serological features, IIM can be classified into several subgroups - dermatomyositis (including amyopathic dermatomyositis), antisynthetase syndrome, immune-mediated necrotizing myopathy, inclusion body myositis, polymyositis and overlap myositis. The prognoses, treatment responses and organ manifestations vary among these groups, implicating different pathophysiological mechanisms in each subtype. A deeper understanding of the molecular pathways underlying the pathogenesis and identifying the auto-antigens of the immune reactions in these subgroups is crucial to improving outcomes. New, more homogeneous subgroups defined by auto-antibodies may help define disease mechanisms and will also be important in future clinical trials for the development of targeted therapies and in identifying biomarkers to guide treatment decisions for the individual patient.
650    _2
$a autoprotilátky $7 D001323
650    12
$a autoimunitní nemoci $x diagnóza $7 D001327
650    12
$a dermatomyozitida $x patologie $x terapie $7 D003882
650    _2
$a lidé $7 D006801
650    _2
$a svalová slabost $7 D018908
650    12
$a myozitida $x diagnóza $x patologie $7 D009220
650    12
$a myozitida s inkluzními tělísky $x patologie $7 D018979
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Intramural $7 D052060
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Fujimoto, Manabu $u Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan $1 https://orcid.org/0000000230624872
700    1_
$a Vencovsky, Jiri $u Institute of Rheumatology, Prague, Czech Republic $u Deptartment of Rheumatology, 1st Medical Faculty, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000208510713 $7 jo20000080529
700    1_
$a Aggarwal, Rohit $u UPMC Myositis Center, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA
700    1_
$a Holmqvist, Marie $u Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden $u Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden $1 https://orcid.org/0000000189965260
700    1_
$a Christopher-Stine, Lisa $u Johns Hopkins Myositis Center, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA $1 https://orcid.org/0000000271507306
700    1_
$a Mammen, Andrew L $u National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA $u Departments of Neurology and Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA $1 https://orcid.org/0000000337323252
700    1_
$a Miller, Frederick W $u Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
773    0_
$w MED00200655 $t Nature reviews. Disease primers $x 2056-676X $g Roč. 7, č. 1 (2021), s. 86
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34857798 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131458 $b ABA008
999    __
$a ok $b bmc $g 1789377 $s 1162952
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 7 $c 1 $d 86 $e 20211202 $i 2056-676X $m Nature reviews. Disease primers $n Nat Rev Dis Primers $x MED00200655
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...